Lead Product(s) : Argatroban Monohydrate
Therapeutic Area : Hematology
Study Phase : Approved
Recipient : Mitsubishi Tanabe Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Acquisition of Argatroban Business in Europe
Details : Ethypharm acquired Mitsubishi Tanabe's selective antithrombin agent Arganova (argatroban monohydrate) in Europe. It is indicated for the treatment of heparin-induced thrombocytopenia type II.
Brand Name : Arganova
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 17, 2024
Lead Product(s) : Argatroban Monohydrate
Therapeutic Area : Hematology
Highest Development Status : Approved
Recipient : Mitsubishi Tanabe Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Mesalazine
Therapeutic Area : Gastroenterology
Study Phase : Approved
Recipient : Anbison
Deal Size : Undisclosed
Deal Type : Acquisition
Ethypharm expands its Mesalazine (Etiasa®) Portfolio in China
Details : The acquisition will enable Ethypharm a full portfolio of Mesalazine forms, including a suppository form of Etiasa (mesalazine), used to treat IBD such as ulcerative colitis and Crohn's disease.
Brand Name : Etiasa
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 13, 2024
Lead Product(s) : Mesalazine
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Recipient : Anbison
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Morphine Sulfate
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Ethypharm Gains EU Approval for Morphine Immediate Release Tablets
Details : Company received marketing authorisations (MA) for the 1st Immediate-Release orodispersible tablets of morphine, an opioid receptor agonist for the management of severe pain.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 02, 2021
Lead Product(s) : Morphine Sulfate
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Celecoxib
Therapeutic Area : Neurology
Study Phase : Approved
Recipient : Dr. Reddy\'s Laboratories
Deal Size : Undisclosed
Deal Type : Acquisition
Ethypharm Reinforces its Late-Stage R&D Pipeline with a Novel Acute Treatment of Migraine
Details : Ethypharm has acquired the exclusive rights for the development, registration and commercialization in the top 5 European markets of a novel celecoxib formulation already approved in the US for the acute treatment of migraine. Celecoxib is developed by D...
Brand Name : Elyxyb
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 19, 2021
Lead Product(s) : Celecoxib
Therapeutic Area : Neurology
Highest Development Status : Approved
Recipient : Dr. Reddy\'s Laboratories
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Study Phase : Approved
Recipient : Orphelia Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
ORPHELIA, Ethypharm Sign Kigabeq® Licensing Deal for China
Details : Orphelia has granted Ethypharm exclusive rights under a license agreement to commercialize Kigabeq (vigabatrin) in China. Kigabeq is indicated as a first-line treatment for infantile spasms.
Brand Name : Kigabeq
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 19, 2021
Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Highest Development Status : Approved
Recipient : Orphelia Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Medexus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Triamcinolone Hexacetonide is a longest-acting corticosteroid for intra articular injection. The companies have agreed to a small upfront fee along with milestone payments at the time of FDA approval, at commercial product launch, and upon certain sales ...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 18, 2020
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Medexus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Cholic Acid
Therapeutic Area : Genetic Disease
Study Phase : Approved
Recipient : Laboratoires CTRS
Deal Size : Undisclosed
Deal Type : Agreement
Ethypharm, CTRS Partner to Register Orphacol® in China
Details : Under the agreement, CTRS has granted Ethypharm exclusive rights to distribute Orphacol (cholic acid) in China. It is indicated for the two rare inborn errors of primary bile acid synthesis.
Brand Name : Orphacol
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 10, 2020
Lead Product(s) : Cholic Acid
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Recipient : Laboratoires CTRS
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Fentanyl
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Recipient : Reading Scientific Services
Deal Size : Undisclosed
Deal Type : Partnership
Ethypharm and RSSL Fast-Track Medicine for COVID-19 Patients
Details : The collaboration is intended to accelerate the manufacture and batch release of fentanyl injection; one of the critical medicines needed for the treatment of COVID-19 patients.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 04, 2020
Lead Product(s) : Fentanyl
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Recipient : Reading Scientific Services
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?
KEY SERVICES
Reset All
Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.